Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025)

Rani Therapeutics Holdings' Total Debt history runs 6 years deep, the most recent figure standing at $13.5 million for Q3 2025.

• On a quarterly basis, Total Debt fell 52.17% year-over-year to $13.5 million in Q3 2025; TTM through Sep 2025 was $13.5 million, a 52.17% decrease from a year earlier, with the FY2024 full-year figure at $24.6 million, down 16.23% from the prior year.
• Total Debt eased to $13.5 million in Q3 2025 per RANI's latest filing, from $17.2 million in the prior quarter.
• Across five years, Total Debt topped out at $29.5 million in Q2 2024 and bottomed at $30000.0 in Q2 2022.
• The 5-year median for Total Debt is $22.8 million (2024), against an average of $18.2 million.
• Across the five-year window, Total Debt plunged 99.23% in 2022 and surged 97450.0% in 2023, its largest moves.
• Year by year, Total Debt stood at $126000.0 in 2021, then soared by 23034.13% to $29.1 million in 2022, then climbed by 0.8% to $29.4 million in 2023, then declined by 16.23% to $24.6 million in 2024, then plunged by 45.0% to $13.5 million in 2025.
• Per Business Quant, the three latest RANI Total Debt figures stand at $13.5 million (Q3 2025), $17.2 million (Q2 2025), and $20.9 million (Q1 2025).